A mixed toxoid consisting of HR1 and HR2 toxoids derived from Habu (Trimeresurus flavoviridis) venom was examined for immunogenicity in guinea pigs, rabbits, monkeys and human beings. The toxoid produced both anti-HR1 and anti-HR2 in various animals.
INTRODUCTION
We described a method to convert Habu venom into toxoid of high immunogenicity by formalinization (Sadahiro et al., 1968 (Sadahiro et al., , 1970 Sadahiro, 1971a,b; . A practical method to determine the potency of the toxoid was also proposed. The results of challenging the immunized guinea pigs with crude venom suggested that Habu toxoid should contain all the main antigens possessed by the crude venom. A mixed toxoid composed of purified HR1 and HR2 toxoids satisfied the requirement . It appeared then interesting to test the, immunogenicity of the toxoid in other animal species and to examine whether the potency determined in guinea pigs would indicate the ability of the toxoid to prevent envenomation by the snake bite. A part of such aexperiments was published in a preliminary 365 Vol.
24 KONDO et al. report (Kondo et al., 1970) . This paper describes details of the experiments on safety and immunogenicity in various animals of a mixed toxoid prepared for human use . The results of a preliminary experiment in a few human volunteers are also presented .
MATERIALS AND METHODS* Animals : Guinea pigs of both sexes weighing 300-400 g and male rabbits weighing about 3 kg were purchased from a dealer . Cynomolgus monkeys (Macaca i rus) weighing 1.8-3.6 kg were used irrespective of sex .
Reference Habu toxoid : A preparation of crude toxoid (No. 7) was used as the reference for the potency test. The parent venom of the reference was a pool of Habu venom (66 B) collected in Amami Islands in 1966; the toxicities were 4 ,200 M HD and 18 LD50 per mg. Toxoid was prepared and adsorbed onto aluminum phosphate gel as described by .
The toxoid preparation was kept in a lyophilized state. Each vial contained 60 mg protein and 27 mg aluminum . Before use it was resuspended in distilled water to contain 3 mg protein and 1 .35 mg aluminum per ml.
Purified mixed toxoid No. 12: A preparation of adsorbed mixed toxoid was produced by the method described by . The parent venom (68 B) was collected in Amami Islands in 1968 and contained 3,700 MHD and 18 LD50 per mg. The toxicities of purified HR1 were 9,100 MHD and 28 LD50 per mg and those of HR2 5,300 MHD and 8 LD50 per mg. After detoxification of each purified toxin, the same amounts of both on protein basis were mixed to prepare the mixed toxoid. Aluminum phosphate was used as an adjuvant.
The final product contained 1 mg of protein and 1.35 mg of aluminum per ml and the pH was 5 .9.
Venom for challenge : The same batch of crude venom (66 B) as used for preparing the reference toxoid was used throughout this experiment.
Method of immunization : Animals received subcutaneous injections with each of graded doses of toxoid preparations.
The injections were repeated three times; the immunized animals were bled at intervals for titration of circulating antitoxins . After the last injections, some animals were challenged intramuscularly at the thigh with various amounts of the crude venom irrespective of the imunizing doses to correlate the antitoxin titers to the resistance to the venom. Animals were autopsied soon after deaths; the surviving animals were incised at the injection site to examine for pathological changes.
Titration of antitoxins : Antitoxins of the immunized animals were determined in terms of anti-HR1, anti-HR2 and anti-lethal toxin . Antitoxins against HR1 and HR2 were determined by the rabbit intracutaneous method and anti-lethal toxin by the mice intravenous method according to the procedures described by Kondo, H, et al. (1965a Kondo, H, et al. ( ,b, 1971 .
Miscellaneous : The toxicities of the crude venom and the purified toxins were tested in terms of hemorrhagic activity and lethality by the methods described by Kondo et al. (1960) and by Ohsaka et al. (1960) . Protein content was estimated by the micro-Kjeldahl method.
Immunogenicity of Toxoids in Guinea Pigs
Groups of 7 guinea pigs received three injections with each of graded doses (0.25 -1 ml) of toxoid (No . 12 or the reference) at 4 weeks' intervals. The time course of the antitoxin production is illustrated in Fig. 1 . The titer rose quickly in response to the first two injections and then the rate of increase slowed down.
The relative potencies (Finney, 1952) on weight basis of No. 12 to the reference toxoid calculated from the circulating antitoxin after the 2nd injection were 8.0 and 0.7, with fiducial limits of 2.4-27.1 and 0.2-2.6 respectively for HR1 and HR2 toxoid. Some immunized animals were challenged with the crude venom 12 days after the last injection, as shown in Table 1 . The mixed toxoid bestowed almost complete protection against 300 ug of the venom and a remarkable protection against 3 mg, whereas the unimmunized animals showed severe hemorrhage followed by necrosis with 300 ug. In separate experiments, severe destruction of the challenged muscle was invariably observed with 1 mg. Table 1 also suggests that the ability of the mixed toxoid to protect against the venom was comparable or rather superior to the reference toxoid. Groups of 7 guinea pigs received three injections with each of the graded doses (0. 25, 0. 5, 1 ml) of the reference or the toxoid No. 12 at intervals of 4 weeks. Logarithmic means of circulating antitoxin in the 0.25 ml and 1 ml groups were plotted.
• 3) Figures in parentheses show titers of circulating antitoxin (unit/ml) determined 10 days after the last injection in the order of anti-HR1 and anti-HR2 .
Immunogenicity of Toxoid No, 12 in Rabbits
The time course of the antitoxin production is shown in Fig . 2 . Table 2 summarizes the results after the challenge 12 days after the 3rd injection . The animals having antitoxin potencies over 10 units per ml showed almost complete resistance against 2 mg of the venom, while unimmunized animals showed severe damage with 1 mg.
Immunogenicity of Toxoids in Monkeys
Monkeys were immunized repeatedly with each of graded doses of a toxoid . Because of the limited number of animals, experiments with the reference toxoid and those with toxoid No. 12 were done separately.
As shown in Fig . 3 and Fig. 4 , antitoxin was detectable even after the first immunization and the titer rose rapidly in response to the first two injections.
Higher titers were obtained with toxoid No . 12. Table 3 summarizes the results of challenge with the venom . When challenged with 10 mg venom, 3 of 6 monkeys in the toxoid No. 12 group survived with slight pathological changes ; whereas all animals in the reference toxoid group died with severe local symptoms. Of the monkeys challenged with 5 mg or less venom all survived in the former group, while one died in the latter . The results suggest that the Groups of 5 rabbits received three injections with each of the graded doses (0.5, 1, 2ml) of the toxoid No. 12 at intervals of 4 weeks. Logarithmic means of circulating antitoxin in the 0.5 ml and 2 ml groups were plotted.
• Three groups of monkeys received three injections with each of the graded doses (0.5, 1, 2ml) of the reference toxoid at intervals of 4 weeks. Number of animals were 4 for the 0 .5 ml group and 8 for the other two groups. Logarithmic means of circulating antitoxin in the 0.5 ml and 2 ml groups were plotted.
•
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•\-•\-Show the lowest detectable level of antitoxin
•ª Shows the injection mixed toxoid was a better antigen than the crude toxoid though the relative potency could not be calculated. Figure 5 summarizes the relationship between antitoxin and resistance. Anti-HR1 alone was considered since HR1, the main component of the venom, is associated with the most part of the lethal toxin and almost all animals showed high titer of anti-HR2.
Animals showing anti-HR1 titers higher than 10 units per ml seem to have high resistance against the venom amounting to 10 mg. Further studies with larger number of animals are necessary to correlate numerically the antitoxin titer to the resistance against the venom.
Safety of Toxoid No. 12
Neither HR1 nor HR2 toxoid contained in toxoid No . 12 showed no toxicity when inoculated intracutaneously into rabbits in an amount of 0 .1 ml, intravenously into mice in 0.2 ml or subcutaneously into mice in 0.5 ml . Mice, rats and guinea pigs were inoculated intraperitoneally, respectively with 0 .5 ml, 2 ml and 5 ml of toxoid No. 12.
The inoculated animals showed no pathological symptoms and the increase of the body weight of the animals was comparable to unimmunized ones . On autopsy after anesthesia with ether, slight fibrinous inflammation with scattered petechiae was observed Three groups of 6-8 monkeys received three injections with each of the graded doses (0. 5, 1, 2 ml) of toxoid No. 12 at intervals of 4 weeks. Logarithmic means of circulating antitoxin in the 0.5 ml and 2 ml groups were plotted ; bleeding was not done after the 1st injection. Animals received 3 injections of Habu toxoids (reference or No. 12) and circulating antitoxins were titrated 10-12 days after the last injection.
Animals were challenged with a crude venom 7 days and 19 days after the bleeding, respectively for the No. 12 toxoid and the reference toxoid groups. The titers of anti-HR1 alone were used in the figure. Unimmunized animals were killed with about 5 mg and servived with severe local symptoms with 2 mg of the challenging venom.
•oe Died 3) See footnote 3) to Table 1. in the peritoneal cavity. However, the findings are common with all other biological products containing aluminum ad juvant, such as adsorbed tetanus toxoid and measles vaccine widely used for human beings. The parent toxoids before mixing with the adjuvant did not show such symptoms. Guinea pigs, rabbits and monkeys receiving 3-4 successive injections of 1-2 ml of the toxoid showed noo abnormal symptoms except for slight induration at the site of injection, that is also a common symptom caused by other toxoids containing adjuvant. Several monkeys were observed for 9 months after 3 successive injections, showing no clinical symptoms due to the injection. No allergic manifestations of any immediate or delayed type were observed when the monkeys were given with a booster injection of 0.5 ml 9 months after the 3rd injection. The product passed the Minimum Requirements for Sterility Test for Biologic Products (Ministry of Health and Welfare, 1965) .
Immunization of Human Volunteers with Toxoid No. 12
Three injections of 0.1, 0.2 or 0.5 ml doses were given intramuscularly into 9 volunteers from our laboratory at intervals of 4 and 20 weeks (11 weeks in some per-IMMUNOGENICITY OF HABU TOXOID sons). Blood samples were taken at intervals and tested for antitoxins. The results are summarized in Table 4 . Both anti-HR1 and anti-HR2 were below the detectable level (0.63 units/ml) before injection.
The titers rose to 2-5 units/ml for HR1 and, 7-21 units/ml for HR2 after the second injection (Table 4 ). The titers of HR1 antitoxin dropped to about half 20 weeks after the 2nd injection, while the decrease in those of anti-HR2 was rather slight.
In response to the booster injection, the titers restored to the same level as that after the 2nd injection.
No untoward reactions: were observed except for slight tenderness and induration at the injection site for 2-3 days among persons inoculated with 0.5 ml doses. Each volunteer received 3 injections at intervals of 4 weeks and 11-20 weeks. They were bled 4 weeks after the 2nd and 2 weeks after the 3rd injections. Antitoxins were below the detectable level (0.63 units/ml) before injection in all persons.
DISCUSSION
The data presented here clearly demonstrate that the mixed toxoid was highly immunogenic in guinea pigs, rabbits and monkeys and confirm the previous observation that the main antigens necessary to protect against crude venom were kept well after purification of the toxic principles. Figures 1, 3 and 4 suggest that the immunogenicity of toxoid No. 12 was superior to the reference toxoid not only in guinea pigs but also in monkeys on the basis of protein injected, though relative potency in monkeys was not calculated. Separate experiments with other lots of preparations also showed that the potency of the purified mixed toxoid was superior to the crude ones (e. g. . The fact that 3 of 6 monkeys showing high anti-HR1 titer survived the challenge with 10 mg of the crude venom supports that the mixed may be useful as a prophylactic against envenomation, since the above amount of the venom is very close to that (about 13 mg) ejected by a single snake bite (Kondo et al., unpublished data) . KONDO et al. Although excellent immunogenicity of the mixed toxoid was confirmed in various animals, immune responses were different depending on the animal species . In guinea pigs and rabbits higher titers were obtained for anti-HR1 than for anti-HR2, while in monkeys and humans the relation was the reverse, as illustrated in Table 5 . This is very important from the practical view-point , since HR1, which the main lethal toxin is always associated with, is the main toxic factor of the crude venom and the anti-lethal toxin is always found in animals in which anti-HR1 titer is higher than anti-HR2 (unpublished).
In the future we will have to prepare a more highly immunogenic HR1 component. 2) For humans 0.2 ml was injected instead of 0.25 ml.
3) (1) Bled 10 days for animals and 4 weeks for humans after the 2nd injection .
(2) Bled 10 days for animals and 14 days for humans after the 3rd injection.
Another difference was that monkeys showing 10-20 units/ml of HR1 antitoxin tolerated satisfactorily, without developing significant local symptoms , 5 mg of the venom; while guinea pigs with similar titers of the antitoxin showed more distinct local symptoms than monkeys with 3 mg of the venom. Other experiments showed that many immunized guinea pigs died with more than 5 mg. The lethal doses for unimmunized animals of both species were around 3-5 mg. Possible reasons for the discrepancy may be: (1) The amount of antilethal toxin , which could not be determined accurately by the present method of titration, may be different depending on the species; (2) the distribution of antitoxins in the blood and the tissue may be different depending on the species; (3) there may be a qualitative difference in antitoxins among animal species; (4) the inoculated venom may more rapidly diffuse in the large muscle tissue of the monkey, resulting in dilution to such a concentration neutralizable with the circulating antitoxin.
No evidences are now available to explain the discrepancy.
The other difference was that the response to the booster immunization seemed to be different depending upon animal species. No rise in the antitoxin titers after the 3 rd immunization was observed in man , while a slight rise was observed in mon-IMMUNOGENICITY OF HABU TOXOID keys, rabbits and guinea pigs. The response to the booster immunization was surprisingly low when compared with that with other toxoids such as diphtheria, tetanus and botulinus toxoids. We are not in the opinion that the antitoxin titers obtained after the second injection of the Habu toxoid was the maximum value obtainable in those animal species, since with another HR1 toxoid guinea pigs produced as high potency as 100-200 units per ml after the second injection (unpublished). Further study is now being made on this point.
Although the anti-HR1 values in man were rather low compared with those in monkeys which tolerated 10 mg of the venom, we are planning to continue the inoculation to human volunteers with toxoid No. 12 for the following reasons : (1) Monkeys possessing anti-HR1 of 5 units/ml and anti-HR2 of 10 units/ml showed a considerable resistance to 5 mg of the venom. (2) Monkeys showed more resistance against the challenge than the guinea pigs with comparable antitoxin titers. (3) Passively administered antivenin in an amount of 6,000-12,000 units per an adult human weighing about 50-60 kg is effective on therapy of envenomation when given soon after the bite. IMMUNOGENICITY OF HABU TOXOID Photograph 1
Local symptom of the monkey challenged with 5 mg crude venom, showing almost complete protection.
Immunization:
Crude toxoid Antitoxin titer before challenge: Anti-HR1 5 u/ml, Anti-HR2 22 u/ml.
Photograph 2
Local symptom of the monkey (unimmunized control) challenged with 5 mg crude venom, showing a severe symptom corresponding to 1 ; died 3 days after the challenge.
